HTB homepage • Conference reports • Articles by subject • Subscribe June 2010 Contents Editorial Volume 11 Number 5/6 May/June 2010 Conference reports 2nd Joint Conference of BHIVA with BASHH, 20-23 April 2010, Manchester HAART use among women in UK receiving treatment prior to conception Duration of ruptured membranes and vertical transmission in the UK Significant rates of unplanned pregnancies among young women born with HIV Route of HCV transmission in HIV-positive gay men is unlikely to be from semen 75% HIV-positive children have insufficient levels of Vitamin D Increase in LGV cases in gay men reported in the UK High rates of osteopenia and osteoporosis: importance of DEXA monitoring Summaries of other studies 11th International Workshop on Clinical Pharmacology of HIV Therapy, 7-9 April, 2010, Sorrento, Italy Atazanavir absorption maximised with food Methadone levels reduced moderately by rilpivirine Maraviroc 150mg once-daily achieves target concentrations with atazanavir/ritonavir Raltegravir and unboosted atazanavir Raltegravir dose adjustment not required for patients on dialysis Raltegravir and darunavir pharmacokinetics in liver disease Tenofovir may require closer renal monitoring in older patients Effect of age on atazanavir, darunavir, raltegravir and etravirine Proposed approach to measuring TDM for raltegravir Increased bilirubin levels when atazanavir is dosed twice-daily 17th Conference on Retroviruses and Opportunistic Infections (CROI) 16-19 February 2010, San Francisco HIV reinfection cases reported at CROI Hepatitis studies: IL28B genetics, HCV survival, FibroScan in acute HCV, MSM reinfection and responses to transplantation Poor bioequivalence with crushed and dissolved tablets Initial PK, safety and 12 week efficacy of raltegravir chewable tablets in children 6-11 years PK of efavirenz in children dosed according to WHO weight bands Virological and immunological responses in infants enrolled in the CHER trial Darunavir-associated mutations in PI-naive and PI-experienced children in the UK HIV persistence, raltegravir/maraviroc intensification and immunology Antiretrovirals START study launched and endorsed by broad community support: over 140 community organisations sign letter to US guideline panel FDA safety updates to antiretroviral labels Development of apricitabine halted without finding backer for Phase 3 Treatment access FDA approval of generic ARVs U.S. government leading backlash against AIDS funding Evidence from six countries confirms fears of People Living With HIV/AIDS: treatment rationing is escalating Launch of the 10th funding round and other outcomes from the Global Fund Pregnancy Pregnancy outcomes with efavirenz Basic science and immunology The antiviral impact of CD8 T cells: much ado about the mechanism Bad to the bone marrow? Cell-free vs cell-associated HIV transmission Coagulation and inflammatory biomarkers in children and adolescents with HIV Pre-infection CD8 T cells targeting HIV linked to lower post-infection viral load Activism & advocacy The HIV Research Catalyst Forum: treatment, prevention, advocacy Experimental HCV drugs for HIV/HCV coinfected people: workshop on trial design AIDS activists detained by Tanzanian authorities at World Economic Forum on Africa Other news China lifts travel ban on people with HIV Malawian courts 14-year sentence for gay men widely condemned Uganda law proposes death penalty for homosexuality: can international reaction and vulnerability of treatment access programmes help? PDFs Volume 11 Number 3/ May/April 2010 PDF HTB homepage • Conference reports • Articles by subject • Subscribe
